Condition
Lentivirus Infections
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownEffectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upNCT07678268 · 2025-07-10
RECRUITINGFeasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima PeruNCT02630082 · 2011-04-01
COMPLETEDMesalamine to Reduce T Cell Activation in HIV InfectionNCT01090102 · 2010-06-01
COMPLETEDStudy of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and TuberculosisNCT05065905 · 2006-01-19
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
COMPLETED3
RECRUITING1
Phase mix
PHASE42
NA1
PHASE11
PHASE21
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.